Yuan-Ni Wu

Yuan-Ni Wu

Auto-generated profile, based on publicly available information

Yuan-Ni Wu

Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Cellular Immunology
Verified
Journal Article
Closed access
YWYuan-Ni Wu
Yuan-Ni Wu
RZRui Zhang
Rui Zhang
XSXin-Cheng Song
Xin-Cheng Song
XHXiao-Xu Han
Xiao-Xu Han
JZJian Zhang
Jian Zhang
XLXin Li
Xin Li

26 December 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
YWYuan-Ni Wu
Yuan-Ni Wu
HYHai Yu
Hai Yu
LLLianfeng Lu
Lianfeng Lu
XLXiaodi Li
Xiaodi Li
XLXiaosheng Liu
Xiaosheng Liu
TLTaisheng Li
Taisheng Li
Background: Current antiretroviral regimens have, for the most part, achieved optimal antiretroviral efficacy and tolerability, transforming HIV infection from a deadly disease into a manageable chronic condition. However, adherence to daily oral drug intake remains an issue, as it is the most important determinant for sustained viral suppression and prevention of the emergence of drug-resistant viral strains. The long-acting injection antiretroviral cabotegravir and rilpivirine combination, a novel drug delivery approach, is about to revolutionise the therapy for people living with HIV. In this protocol, we aim to generate a clinically useful summary of the interventions based on their efficacy. Methods and analysis: We searched the literature for eligible studies published from inception up to 16 August 2022 through PubMed, EMBASE, Cochrane Library, Scopus and ClinicalTrials.gov. Two methodologically trained researchers will select the qualified studies for data extraction independently. Cochrane Risk of Bias tool will be used to assess the risk of bias in included studies. Statistical heterogeneity will be computed by Cochrane X2 and I2 tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Publication biases will be evaluated by Begg’s and Egger’s tests. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation system. The RevMan V.5.3 and Stata V.14.0 software will be applied for statistical analyses. Ethics and dissemination: Ethical approval will not be required for this systematic review because the data used are not linked to the individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal. PROSPERO registration number: CRD42022310414